Targets › ELANE
6 programs from 6 companies in 7 trials: 3 Phase 1, 2 Phase 2, 1 Phase 4, 1 Phase 3; Respiratory, Oncology, Gastroenterology; next expected readout Jul 2027.
Serine protease that modifies the functions of natural killer cells, monocytes and granulocytes. Shows microbicidal activity in neutrophils by mediating cleavage and degradation of bacterial proteins. (UniProt, P08246)
Open in Phaseline: the race on ELANE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CSL Behring | .Alpha.1-Proteinase Inhibitor Human (CE1226) Leukocyte elastase inhibitor | ELANE | Phase 4 | Alpha1 Antitrypsin Deficiency; Eosinophilic Esophagitis | Sep 2033 |
| Grifols Therapeutics | .Alpha.1-Proteinase Inhibitor Human Leukocyte elastase inhibitor | ELANE | Phase 3 | Pulmonary Emphysema in Alpha-1 PI Deficiency | – |
| Affiliated Hospital of Nantong University | Sivelestat Sodium Neutrophil elastase inhibitor | ELANE | Phase 2 | Coronary Heart Disease | Jul 2027 |
| National Cancer Institute (NCI) | Alvelestat (MPH966) Leukocyte elastase inhibitor | ELANE | Phase 1 | Chronic Graft vs Host Disease | Dec 2027 |
| Kyushu University | Sivelestat sodium hydrate Neutrophil elastase inhibitor | ELANE | Phase 1 | Neuromyelitis Optica Spectrum Disorder Attack | Jan 2028 |
| Onchilles Pharma | N17350 Recombinant mutant porcine pancreatic elastase (PPE) targeting the neutrophil elastase (EL | ELANE | Phase 1 | Neoplasms, Solid Tumor | Jul 2028 |
Neoplasms, Solid Tumor (1) Alpha1 Antitrypsin Deficiency (1) Eosinophilic Esophagitis (1) Coronary Heart Disease (1) Neuromyelitis Optica Spectrum Disorder Attack (1) Chronic Graft vs Host Disease (1) Pulmonary Emphysema in Alpha-1 PI Deficiency (1)
protein or peptide (3), small molecule (3)
Onchilles Pharma (1) CSL Behring (1) Affiliated Hospital of Nantong University (1) Kyushu University (1) National Cancer Institute (NCI) (1) Grifols Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.